|
Video: What is a Stock Split?
|
|
Albireo Pharma is a commercial-stage biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Co.'s product pipeline includes: Bylvay, which is approved in the U.S. and Europe for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its primary candidate for the treatment of adult liver diseases; and A2342, its primary preclinical candidate for the treatment of adult viral and liver diseases. According to our ALBO split history records, ALBO has had 1 split. | |
|
ALBO (ALBO) has 1 split in our ALBO split history database. The split for ALBO took place on November 04, 2016. This was a 1 for 30 reverse split, meaning for each 30 shares of ALBO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as ALBO conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ALBO split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ALBO shares, starting with a $10,000 purchase of ALBO, presented on a split-history-adjusted basis factoring in the complete ALBO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/22/2015 |
|
End date: |
03/02/2023 |
|
Start price/share: |
$41.40 |
|
End price/share: |
$44.15 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
6.64% |
|
Average Annual Total Return: |
0.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,667.75 |
|
Years: |
8.11 |
|
|
|
Date |
Ratio |
11/04/2016 | 1 for 30 |
|
|